Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin
- PMID: 24256846
- PMCID: PMC3868322
- DOI: 10.1093/annonc/mdt409
Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin
Abstract
Background: The different perception and assessment of chemotherapy-induced peripheral neurotoxicity (CIPN) between healthcare providers and patients has not yet been fully addressed, although these two approaches might eventually lead to inconsistent, possibly conflicting interpretation, especially regarding sensory impairment.
Patients and methods: A cohort of 281 subjects with stable CIPN was evaluated with the National Cancer Institute-Common Toxicity Criteria (NCI-CTC v. 2.0) sensory scale, the clinical Total Neuropathy Score (TNSc©), the modified Inflammatory Neuropathy Cause and Treatment (INCAT) sensory sumscore (mISS) and the European Organization for Research and Treatment of Cancer CIPN specific self-report questionnaire (EORTC QOL-CIPN20).
Results: Patients' probability estimates showed that the EORTC QLQ-CIPN20 sensory score was overall more highly related to the NCI-CTC sensory score. However, the vibration perception item of the TNSc had a higher probability to be scored 0 for EORTC QLQ-CIPN20 scores lower than 35, as vibration score 2 for EORTC QLQ-CIPN20 scores between 35 and 50 and as grade 3 or 4 for EORTC QLQ-CIPN20 scores higher than 50. The linear models showed a significant trend between each mISS item and increasing EORTC QLQ-CIPN20 sensory scores.
Conclusion: None of the clinical items had a perfect relationship with patients' perception, and most of the discrepancies stood in the intermediate levels of CIPN severity. Our data indicate that to achieve a comprehensive knowledge of CIPN including a reliable assessment of both the severity and the quality of CIPN-related sensory impairment, clinical and PRO measures should be always combined.
Keywords: assessment; chemotherapy; neuropathy; neurotoxicity; patient-reported outcome measure.
Figures


Similar articles
-
Repurposing chemotherapy-induced peripheral neuropathy grading.Eur J Neurol. 2024 Dec;31(12):e16457. doi: 10.1111/ene.16457. Epub 2024 Sep 16. Eur J Neurol. 2024. PMID: 39282967 Free PMC article.
-
Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials.Support Care Cancer. 2017 Nov;25(11):3537-3544. doi: 10.1007/s00520-017-3780-y. Epub 2017 Jun 20. Support Care Cancer. 2017. PMID: 28634656 Free PMC article.
-
Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).Asia Pac J Clin Oncol. 2019 Feb;15(1):56-62. doi: 10.1111/ajco.13000. Epub 2018 Jun 5. Asia Pac J Clin Oncol. 2019. PMID: 29873180
-
[Chemotherapy-induced peripheral neuropathy; impact on quality of life].Ned Tijdschr Geneeskd. 2014;158:A7455. Ned Tijdschr Geneeskd. 2014. PMID: 25315326 Review. Dutch.
-
Chemotherapy-induced peripheral neurotoxicity.Curr Opin Neurol. 2015 Oct;28(5):500-7. doi: 10.1097/WCO.0000000000000234. Curr Opin Neurol. 2015. PMID: 26197027 Review.
Cited by
-
Chemotherapy-induced peripheral neuropathy in African American cancer survivors: Risk factors and quality of life outcomes.Cancer Med. 2021 Nov;10(22):8151-8161. doi: 10.1002/cam4.4328. Epub 2021 Oct 23. Cancer Med. 2021. PMID: 34687150 Free PMC article.
-
Psychometric Testing of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization and Alliance for Clinical Trials in Oncology A151408 Study Data.Cancer Nurs. 2019 May/Jun;42(3):179-189. doi: 10.1097/NCC.0000000000000596. Cancer Nurs. 2019. PMID: 29649081 Free PMC article.
-
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20).Qual Life Res. 2017 Nov;26(11):2999-3010. doi: 10.1007/s11136-017-1626-1. Epub 2017 Jun 20. Qual Life Res. 2017. PMID: 28634676
-
Comparison of nab-paclitaxel, paclitaxel, and oxaliplatin-induced peripheral neuro-pathy: a cross-sectional cohort study.Acta Oncol. 2025 Apr 15;64:527-533. doi: 10.2340/1651-226X.2025.42935. Acta Oncol. 2025. PMID: 40230322 Free PMC article.
-
Chemotherapy-induced peripheral neuropathy clinical trials: Review and recommendations.Neurology. 2017 Aug 22;89(8):859-869. doi: 10.1212/WNL.0000000000004272. Epub 2017 Jul 26. Neurology. 2017. PMID: 28747442 Free PMC article.
References
-
- Frigeni B, Piatti M, Lanzani F, et al. Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale. J Peripher Nerv Syst. 2011;16:228–236. - PubMed
-
- Cavaletti G, Frigeni B, Lanzani F, et al. Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer. 2010;46:479–494. - PubMed
-
- Cavaletti G, Frigeni B, Lanzani F, et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst. 2007;12:210–215. - PubMed
-
- Cavaletti G, Bogliun G, Marzorati L, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology. 2003;61:1297–1300. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical